newsfilter
← Latest News
Business Wire·

Cyteir Therapeutics Reports First Quarter 2022 Financial Results and Operational Highlights

- Safety and efficacy data expected for second half 2022 for CYT-0851 monotherapy and combination studies - CYT-0851 mechanism of action identified as inhibition of monocarboxylate transporter (MCT) activity; new findings potentially expand future op